Kura Oncology, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $67.5M | $53.9M | $0 | — | — |
| Selling, general & administrative | $120.0M | $77.1M | $50.6M | — | — |
| Research and development | $251.1M | $170.0M | $115.2M | $92.8M | $84.7M |
| Operating expenses | $371.1M | $247.1M | $165.8M | $139.9M | $131.3M |
| Operating income | -$303.6M | -$193.2M | -$165.8M | -$139.9M | — |
| Interest expense | $1.5M | $1.6M | $1.5M | $229,000 | $414,000 |
| Pretax income | -$278.4M | -$172.0M | -$152.6M | -$135.8M | — |
| Income tax expense | $297,000 | $2.0M | $0 | $0 | $0 |
| Net income | -$278.7M | -$174.0M | -$152.6M | -$135.8M | -$130.5M |
| Balance Sheet | |||||
| Cash and equivalents | $149.1M | $224.5M | $37.3M | $51.8M | $90.7M |
| Current assets | $708.7M | $744.8M | $432.5M | $446.4M | $522.3M |
| Total assets | $738.4M | $760.2M | $448.9M | $456.3M | $534.1M |
| Current liabilities | $117.0M | $78.7M | $35.3M | $24.1M | $22.5M |
| Total liabilities | $564.2M | $346.5M | $51.7M | $36.0M | $27.4M |
| Stockholders' equity | $174.1M | $413.6M | $397.3M | $420.3M | $506.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$64.1M | $134.3M | -$124.8M | -$110.1M | -$104.6M |
| Depreciation and amortization | $1.0M | $848,000 | $849,000 | $759,000 | $558,000 |
| Stock-based compensation | $37.1M | $33.9M | $28.1M | $26.3M | $23.6M |
| Capital expenditure | $6.6M | $472,000 | $168,000 | $626,000 | $1.1M |
| Free cash flow | -$70.7M | $133.8M | -$125.0M | -$110.7M | -$105.7M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 88.8M · Free float 97.8%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.